Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Net Income towards Common Stockholders (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Net Income towards Common Stockholders data on record, last reported at -$15.1 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 3.71% year-over-year to -$15.1 million; the TTM value through Dec 2025 reached -$59.9 million, down 41.81%, while the annual FY2025 figure was -$59.8 million, 41.54% down from the prior year.
  • Net Income towards Common Stockholders reached -$15.1 million in Q4 2025 per CTNM's latest filing, down from -$12.8 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $41.6 million in Q2 2023 and bottomed at -$16.0 million in Q2 2025.
  • Average Net Income towards Common Stockholders over 3 years is -$6.6 million, with a median of -$9.6 million recorded in 2024.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 121.66% in 2024, then fell 3.71% in 2025.
  • A 3-year view of Net Income towards Common Stockholders shows it stood at -$7.8 million in 2023, then plummeted by 87.04% to -$14.6 million in 2024, then fell by 3.71% to -$15.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$15.1 million in Q4 2025, -$12.8 million in Q3 2025, and -$16.0 million in Q2 2025.